(DOX) Amdocs - NASDAQ
Sector: Technology | Industry: Software - Infrastructure | Exchange: NASDAQ (USA) | Market Cap: 5.464m USD | Total Return: -42.2% in 12m
Avg Turnover: 78.0M
EPS Trend: 99.3%
Qual. Beats: 0
Rev. Trend: -76.1%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
Shakeout
Amdocs Limited (NASDAQ: DOX) provides software and services to communications, entertainment, media, and other service providers worldwide. The company designs, develops, operates, implements, supports, and markets an open and modular cloud offering. It also offers CES25, a telco-native, GenAI-led customer experience suite spanning business, operations, and network domains, along with a portfolio that includes the Customer Engagement Platform, Amdocs Monetization Suite, Amdocs Intelligent Networking Suite, Amdocs Charging, Amdocs eSIM Cloud, Amdocs MarketONE, Amdocs connectX, and Amdocs CatalogONE.
In addition, Amdocs provides consulting, experience design, data, cloud, network services, delivery, quality engineering, systems integration, and content services, as well as maintenance, enhancement, operational support, network deployment and optimization, and managed services featuring AI tools, predictive analytics, and robotic process automation. The company was founded in 1982 and is headquartered in Saint Louis, Missouri.
Amdocs operates in the IT Consulting & Other Services sub-industry within the Information Technology sector, focusing on B2B software and services sold primarily to telecom and media operators. Its offerings include both perpetual/on-premise software and SaaS-based platforms, such as Amdocs MarketONE and connectX, aligning with the broader industry shift toward cloud-native, subscription-based delivery models.
- Telecom operator capex cuts weigh on services revenue
- CES25 GenAI suite adoption accelerates digital transformation deals
- Aggressive share buybacks boost earnings per share growth
| Net Income: 546.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.96 > 1.0 |
| NWC/Revenue: -0.65% < 20% (prev 4.64%; Δ -5.30% < -1%) |
| CFO/TA 0.12 > 3% & CFO 792.8m > Net Income 546.5m |
| Net Debt (1.02b) to EBITDA (942.3m): 1.09 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.5m) vs 12m ago -4.48% < -2% |
| Gross Margin: 37.33% > 18% (prev 36.55%; Δ 0.78% > 0.5%) |
| Asset Turnover: 73.56% > 50% (prev 76.59%; Δ -3.03% > 0%) |
| Interest Coverage Ratio: 18.05 > 6 (EBIT TTM 735.9m / Interest Expense TTM 40.8m) |
| A: -0.00 (Total Current Assets 1.52b - Total Current Liabilities 1.55b) / Total Assets 6.36b |
| B: 1.15 (Retained Earnings 7.34b / Total Assets 6.36b) |
| C: 0.12 (EBIT TTM 735.9m / Avg Total Assets 6.28b) |
| D: 1.15 (Book Value of Equity 3.38b / Total Liabilities 2.94b) |
| Altman-Z'' = 5.73 = AAA |
| DSRI: 1.01 (Receivables 938.2m/957.9m, Revenue 4.62b/4.75b) |
| GMI: 0.98 (GM 36.55% / 37.33%) |
| AQI: 1.02 (AQ_t 0.62 / AQ_t-1 0.61) |
| SGI: 0.97 (Revenue 4.62b / 4.75b) |
| TATA: -0.04 (NI 546.5m - CFO 792.8m) / TA 6.36b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of June 23, 2026, the stock is trading at USD 51.69 with a total of 2,575,120 shares traded. Over the past week, the price has changed by -8.35%, over one month by -17.51%, over three months by -19.90% and over the past year by -42.20%.
Current recommended Stop Loss: 28.10 (which is 45.6% or 11.7 ATR below the current price).
Amdocs has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy DOX.
- StrongBuy: 3
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.2 | 57.1% |
P/E Trailing = 10.2735
P/E Forward = 6.2383
P/S = 1.1821
P/B = 1.6156
P/EG = 0.6932
Revenue TTM = 4.62b USD
EBIT TTM = 735.9m USD
EBITDA TTM = 942.3m USD
Long Term Debt = 647.2m USD (from longTermDebt, last quarter)
Short Term Debt = 286.0m USD (from shortTermDebt, last quarter)
Debt = 1.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 170.6m
Net Debt = 1.02b USD (calculated: Debt 1.24b - CCE 214.5m)
Enterprise Value = 6.49b USD (5.46b + Debt 1.24b - CCE 214.5m)
Interest Coverage Ratio = 18.05 (Ebit TTM 735.9m / Interest Expense TTM 40.8m)
EV/FCF = 9.56x (Enterprise Value 6.49b / FCF TTM 678.7m)
FCF Yield = 10.46% (FCF TTM 678.7m / Enterprise Value 6.49b)
FCF Margin = 14.68% (FCF TTM 678.7m / Revenue TTM 4.62b)
Net Margin = 11.82% (Net Income TTM 546.5m / Revenue TTM 4.62b)
Gross Margin = 37.33% ((Revenue TTM 4.62b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 37.04%)
Tobins Q-Ratio = 1.02 (Enterprise Value 6.49b / Total Assets 6.36b)
Interest Expense / Debt = 3.29% (Interest Expense 40.8m / Debt 1.24b)
Taxrate = 19.70% (134.7m / 683.9m)
NOPAT = 591.0m (EBIT 735.9m * (1 - 19.70%))
Current Ratio = 0.98 (Total Current Assets 1.52b / Total Current Liabilities 1.55b)
Debt / Equity = 0.37 (Debt 1.24b / totalStockholderEquity, last quarter 3.38b)
Debt / EBITDA = 1.09 (Net Debt 1.02b / EBITDA 942.3m)
Debt / FCF = 1.51 (Net Debt 1.02b / FCF TTM 678.7m)
Total Stockholder Equity = 3.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.70% (Net Income 546.5m / Total Assets 6.36b)
RoE = 15.91% (Net Income TTM 546.5m / Total Stockholder Equity 3.43b)
RoCE = 18.03% (EBIT 735.9m / Capital Employed (Equity 3.43b + L.T.Debt 647.2m))
RoIC = 12.09% (NOPAT 591.0m / Invested Capital 4.89b)
WACC = 6.97% (E(5.46b)/V(6.70b) * Re(7.95%) + D(1.24b)/V(6.70b) * Rd(3.29%) * (1-Tc(0.20)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.40 | Cagr: -3.12%
[DCF] Terminal Value 77.62% ; FCFF base≈648.0m ; Y1≈728.8m ; Y5≈1.02b
[DCF] Fair Price = 135.8 (EV 15.4b - Net Debt 1.02b = Equity 14.4b / Shares 106.2m; r=8.35% [WACC [floored]]; 5y FCF grow 12.76% → 2.50% )
EPS Correlation: 99.29 | EPS CAGR: 8.67% | SUE: 0.69 | # QB: 0
Revenue Correlation: -76.13 | Revenue CAGR: -2.96% | SUE: 0.95 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.84 | Chg30d=-2.09% | Revisions=-43% | Analysts=4
EPS current Year (2026-09-30): EPS=7.41 | Chg30d=-0.73% | Revisions=+0% | GrowthEPS=+6.0% | GrowthRev=+3.4%
EPS next Year (2027-09-30): EPS=8.09 | Chg30d=-0.04% | Revisions=+43% | GrowthEPS=+9.2% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -43%